The Short Answer
- Semax is a synthetic heptapeptide (seven amino acids) built from a fragment of the hormone ACTH, ACTH(4-7), plus a Pro-Gly-Pro (PGP) tail. It has been studied for decades, mostly in Russia, where it's been used for stroke. It is not FDA-approved.
- Adamax is a newer product that sellers describe as a modified Semax (usually as Semax with an added adamantane group). As of October 2026, a PubMed search for Adamax returns no peer-reviewed studies of it as a peptide. Its claimed advantages over Semax are marketing claims, not published findings.
So the real comparison is a peptide with an imperfect but real research history vs one with essentially none.
This is an educational comparison. It doesn't give dosing advice. Talk with a licensed clinician about any treatment.
Side-by-Side
| Semax | Adamax | |
|---|---|---|
| What it is | ACTH(4-7) fragment + Pro-Gly-Pro | Marketed as a modified Semax |
| Published human research | Yes, mostly Russian studies, often small | None found on PubMed (Oct 2026) |
| Studied for | Stroke recovery, cognitive effects | No published studies |
| FDA approval | No | No |
| FDA compounding status | Nominated for the 503A Bulks List; reviewed by FDA's advisory committee July 24, 2026; not on the list | Not nominated |
| Identity checks | Possible against published references | No published reference standard |
What Semax Research Actually Shows
Semax's research comes mostly from Russian institutions. Two examples:
- Stroke rehab study (2018): 110 people after ischemic stroke, split by early vs late rehabilitation and whether they received Semax. The authors reported Semax raised blood BDNF (a growth factor for nerve cells) and was associated with better Barthel index (daily-function) scores. It was not a large, placebo-controlled Western-style trial.
- Rat ischemia study (2010): Semax and its PGP tail increased the activity of genes for neurotrophins (nerve growth factors) and their receptors after experimental stroke in rats.
The honest read: interesting mechanism signals and clinical use in Russia, but not the kind of large, independent, placebo-controlled trials FDA relies on. Claims about focus, memory or "nootropic" effects in healthy people are mostly extrapolated.
Why "Adamax Is Stronger" Is a Claim, Not a Finding
Seller pages often describe Adamax as longer-lasting or more potent than Semax. We couldn't find a single peer-reviewed paper testing that. Without published data:
- There's no verified potency or duration comparison.
- There's no published safety data in humans.
- There's no reference standard a lab can use to confirm what's in the vial.
A chemical modification can change how a molecule behaves, for better or worse. That's exactly why it needs to be tested rather than assumed.
FDA Status
FDA's page on bulk substances that "may present significant safety risks" lists Semax (heptapeptide) among substances previously in Category 2 whose nominations were withdrawn. It says compounded Semax "may pose risk for immunogenicity" due to aggregation and peptide-related impurities, and that FDA has "no, or limited, safety-related information" for proposed routes.
Semax was then reviewed by FDA's Pharmacy Compounding Advisory Committee on July 24, 2026 for possible inclusion on the 503A Bulks List. An advisory vote is not a decision: FDA still has to act before Semax could be routinely compounded. See our Semax PCAC explainer for details.
Adamax isn't part of that process at all.
